Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04879173
Other study ID # Project name 2
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 14, 2020
Est. completion date October 2022

Study information

Verified date May 2021
Source Seoul St. Mary's Hospital
Contact Dong Jun Lim, MD,PhD
Phone 82222581220
Email ldj6026@catholic.ac.kr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to verify the clinical value of thyroid ultrasound with microvascular flow imaging in thyrotoxic patients for differential diagnosis between hyperthyroidism and thyroiditis. We intend to use the RS85 Ultrasound device manufactured by Samsung Medison. Graves' disease and painless thyroiditis/subacute thyroiditis are the main cause of thyrotoxicosis. Precise discrimination between Graves' disease and painless thyroiditis/subacute thyroiditis is clinically very important in determining treatment methods, such as the prescription of antithyroid drugs. Primary endpoint was to verify the value of vascularity index, defined by Blood pixel in range of image / Total pixel in range of image .Seondary endpoint was to verify the superiority value of Microvascular flow imaging to discriminate thyrotoxicosis patients compared with Color doppler/ Power doppler ultrasound imaging and conventional ultrasound imaging.


Description:

Thyrotoxicosis refers to the appearance of various clinical symptoms or signs due to and excessive increase of thyroid hormone in the body. Graves' disease, which causes thyrotoxicosis, is one of the most common autoimmune diseases and is known to account for 0.5% of the population. Precise discrimination between Graves' disease and painless thyroiditis/subacute thyroiditis is clinically very important in determining treatment methods. The Microvascular flow imaging technology is expected to show higher sensitivity and accuracy than conventional color Doppler images in differentiating patients between Graves' disease and painless thyroiditis/subacute thyroiditis. We enrolled thyrotoxicosis patients in their initial presentation and used RS85 Ultrasound device manufactured by Samsung Medison to discriminate Graves' disease and painless thyroiditis/subacute thyroiditis. Power / Color doppler ultrasound imaging and conventional ultrasound imaging were used. Tranverse and longitudinal plane of the dominant lobe were selected for imaging. Doppler Adler's method was used to asscess vascularization. To assess the vascularity index, which is defined by Blood pixel in range of image / Total pixel in range of image, we selected the total tranverse plane of the thyroid as range of image.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date October 2022
Est. primary completion date October 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Initial presentation with thyrotoxicosis Exclusion Criteria: - Past history of thyroidectomy - Factitious thyrotoxicosis - Unable for ultrasound

Study Design


Intervention

Device:
RS85 Ultrasound device
RS85 Ultrasound device manufactured by Samsung Medison

Locations

Country Name City State
Korea, Republic of Seoul St. Mary hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Dong Jun Lim

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary The optimal value of vascular index for differentiating the thyrotoxicosis reason 12 months
Secondary The superiority value of Microvascular flow imaging 12 months
See also
  Status Clinical Trial Phase
Completed NCT04304794 - Iodinated Contrast Media Induced Hyperthyroidism
Completed NCT05512715 - LIthium as Bridging thErapy Prior to Radioactiveiodine in hyperThYroidism Phase 4
Active, not recruiting NCT06305871 - Clinical Study of Ultrasound-guided Radiofrequency Ablation in the Treatment of Refractory Hyperthyroidism N/A